Taken together, we report here that C1, the first molecular glue of eEF2K, possesses strong anti‐cancer activity in vitro, in vivo, and in TNBC organoids, and elicits a synergistic tumor inhibitory effect with PTX. Here, EEF2K is linked to neoplasm.